1. Clinical Overview
Levo-carnitine (L-carnitine) is a naturally occurring amino acid derivative (trimethylated amino acid) essential for the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation and energy production. It is a conditionally essential nutrient, meaning endogenous synthesis may be insufficient in certain disease states or physiological conditions. The 500mg oral formulation is widely used in India for the treatment of primary and secondary carnitine deficiencies, and as adjunctive therapy in various conditions associated with impaired energy metabolism.
| Onset | Duration | Bioavailability |
|---|---|---|
| Peak plasma concentrations (Tmax) are typically reached within 3-4 hours after oral administration. | The pharmacodynamic effects (e.g., on fatty acid oxidation) correlate with plasma levels. Effects may be sustained with regular dosing, but the elimination half-life necessitates multiple daily doses for stable levels. | Approximately 5-18% for oral L-carnitine. Bioavailability is significantly reduced (to <10%) with high oral doses due to saturable active transport in the intestine and kidneys. |
2. Mechanism of Action
L-carnitine's primary role is to facilitate the transport of activated long-chain fatty acids (as acyl-CoA esters) across the inner mitochondrial membrane, which is impermeable to CoA esters. It acts as a substrate for carnitine palmitoyltransferase I (CPT I) on the outer mitochondrial membrane, forming acylcarnitine. This complex is shuttled across the membrane via carnitine-acylcarnitine translocase (CACT). Inside the matrix, carnitine palmitoyltransferase II (CPT II) regenerates acyl-CoA and free carnitine. Carnitine also modulates the intramitochondrial acyl-CoA/CoA-SH ratio, preventing acyl-CoA accumulation and promoting oxidative metabolism.
3. Indications & Uses
- Primary systemic carnitine deficiency (SCD)
- Secondary carnitine deficiency due to: Inborn errors of metabolism (e.g., organic acidurias, mitochondrial disorders), Chronic renal disease on hemodialysis
- Adjunctive therapy in angina pectoris and chronic stable angina (to improve exercise tolerance)
4. Dosage & Administration
Adult Dosage: For deficiency states: 990 mg to 2,970 mg per day in 2-3 divided doses. For adjunctive therapy (e.g., angina, neuropathy): 500 mg to 1,500 mg per day in 2-3 divided doses. A common regimen is 500 mg twice or thrice daily.
Administration: Administer with or after meals to improve tolerance and reduce gastrointestinal side effects. Capsules/tablets should be swallowed whole with a glass of water. Oral solution can be taken directly or mixed with water/juice.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Abdominal cramps
- Diarrhea
- Body odor (fishy odor due to bacterial metabolism of excess carnitine to trimethylamine)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Valproic Acid / Valproate | Valproate depletes carnitine levels by forming valproylcarnitine and inhibiting renal reabsorption. L-carnitine supplementation is often required. | Major |
| Anticoagulants (Warfarin, Acenocoumarol) | L-carnitine may potentiate anticoagulant effect, increasing INR and bleeding risk. Monitor INR closely. | Moderate |
| Thyroid Hormones (Levothyroxine) | Theoretical interaction - L-carnitine may inhibit thyroid hormone entry into cells. Clinical significance is unclear but monitor thyroid function. | Minor |
| Doxorubicin | L-carnitine may have a protective effect against doxorubicin-induced cardiotoxicity. Considered beneficial. | Moderate (Beneficial) |
7. Patient Counselling
- DO take the medicine as prescribed, with meals if stomach upset occurs.
- DO inform your doctor if you are on blood thinners (like warfarin) or have kidney problems.
- DO maintain adequate hydration.
- DONT stop taking the medicine suddenly if prescribed for a metabolic disorder.
- DONT take double doses to make up for a missed dose.
8. Toxicology & Storage
Overdose: Diarrhea, nausea, abdominal cramps, and fishy body odor are the most common. Severe overdose could theoretically lead to seizures or arrhythmias, but reports are extremely rare.
Storage: Store in a cool, dry place, away from direct sunlight and moisture. Keep the container tightly closed. Do not freeze. Keep out of reach of children. Oral solutions should be used within the period specified after opening (typically 1-2 months).